U.S. markets open in 4 hours 6 minutes

AXIM Biotechnologies, Inc. (AXIM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0649+0.0029 (+4.68%)
At close: 03:50PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0620
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0615 - 0.0649
52 Week Range0.0610 - 1.2200
Avg. Volume375,776
Market Cap9.865M
Beta (5Y Monthly)2.49
PE Ratio (TTM)N/A
EPS (TTM)-0.1220
Earnings DateMay 01, 2018 - May 07, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AXIM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: Aurora Cannabis Inc.Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that include Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application

    SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has developed a novel tear sample collector system and has filed for a provisional patent application for it with the U.S. Patent and Trademark Office. Tear fluid analysis is a non-invasive method to obtain valuable information about the health condition of various ocul

  • GlobeNewswire

    AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests

    SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Disease (DED), announced today that it has successfully developed a rapid quantitative tear test for Lacritin, a tear protein that autonomously promotes tearing and is deficient in all forms of Dry Eye Disease. While Dry Eye Disease knowingly affects approximately 6.8% of the U.S. population, an estimat

  • GlobeNewswire

    AXIM Biotechnologies CEO Issues Letter to Shareholders

    Summary: AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic systemPlans to address largely underserved DED diagnosis market with patent pending tear collection method and approved tests, supported by world-class DED management teamSupply agreements in place to fulfill demand for DED readers and test strips, creating large revenue opportunityPlans to submit a Phase II grant to further oncological programCompany places emphasis on generating positive cash f